Xeris Biopharma Holdings, Inc. (XERS) stock
XERSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$16.80+0.10 (+0.60%)
Close on Nov 17, 2026Market cap $3.06BP/E –Yield –
Xeris Biopharma ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Xeris Biopharma's ebitda for the twelve months ending Jun 30, 2026 was $37.93M. For fiscal 2025 it was $26.21M. The highest annual figure on record is $26.21M in fiscal 2025.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $26.21M | – |
| FY2024 | Dec 31, 2024 | -$32.42M | – |
| FY2023 | Dec 31, 2023 | -$42.52M | – |
| FY2022 | Dec 31, 2022 | -$80.54M | – |
| FY2021 | Dec 31, 2021 | -$113.83M | – |
| FY2020 | Dec 31, 2020 | -$82.08M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $5.50M | +14.3% |
| Q1 FY2026 | Mar 31, 2026 | $8.25M | – |
| Q4 FY2025 | Dec 31, 2025 | $17.11M | +758.8% |
| Q3 FY2025 | Sep 30, 2025 | $7.07M | – |
| Q2 FY2025 | Jun 30, 2025 | $4.81M | – |
| Q1 FY2025 | Mar 31, 2025 | -$2.78M | – |
| Q4 FY2024 | Dec 31, 2024 | $1.99M | – |
| Q3 FY2024 | Sep 30, 2024 | -$12.59M | – |
| Q2 FY2024 | Jun 30, 2024 | -$7.91M | – |
| Q1 FY2024 | Mar 31, 2024 | -$13.92M | – |
| Q4 FY2023 | Dec 31, 2023 | -$9.50M | – |
| Q3 FY2023 | Sep 30, 2023 | -$4.52M | – |
| Q2 FY2023 | Jun 30, 2023 | -$15.59M | – |
| Q1 FY2023 | Mar 31, 2023 | -$12.91M | – |
| Q4 FY2022 | Dec 31, 2022 | -$14.80M | – |
| Q3 FY2022 | Sep 30, 2022 | -$18.42M | – |
| Q2 FY2022 | Jun 30, 2022 | -$18.56M | – |
| Q1 FY2022 | Mar 31, 2022 | -$28.75M | – |
| Q4 FY2021 | Dec 31, 2021 | -$47.92M | – |
| Q3 FY2021 | Sep 30, 2021 | -$24.04M | – |
| Q2 FY2021 | Jun 30, 2021 | -$25.47M | – |
| Q1 FY2021 | Mar 31, 2021 | -$16.40M | – |
| Q4 FY2020 | Dec 31, 2020 | -$18.90M | – |
See a number that looks wrong?